Key result
Digitalis remains a cost-effective agent that reduces hospitalization for congestive heart failure and may prevent left ventricular dysfunction in uncomplicated hypertension.
Why the study?
Does digitalis provide clinical benefits in patients with various cardiovascular conditions?
Does digitalis provide clinical benefits in patients with various cardiovascular conditions?
Digitalis remains a cost-effective agent that reduces heart failure hospitalizations and may have expanded indications in uncomplicated hypertension.
Answers are grounded in this paper and cite their sources.
Supports digitalis re-evaluation in HF; leaves open prospective RCTs for hypertension indications.
SUMMARY Digitalis has been an old but reliable drug for 240 years. Concerns regarding its clinical indications and benefits still exist in the absence of a reduction in all‐cause mortality. While intravenous digitalis is used without question in cases of atrial fibrillation, it is still controversial in sinus rhythm, despite the Digitalis Investigation Group (DIG) study showing a significant reduction in death and the need for hospitalisation for congestive heart failure in both diastolic and systolic dysfunction. The influence of digitalis in acute myocardial infarction, coronary artery disease and sudden cardiac death remains speculative. In cases of uncomplicated hypertension, it appears to prevent the onset of left ventricular dysfunction and myocardial infarction. Thus, digitalis can be a cost‐effective agent with added benefits.
No takes yet. Share an insight, caveat, or question.
Abarquez Rf (2001) conducted a review in Heart failure, atrial fibrillation, hypertension. Digitalis was evaluated. Digitalis remains a cost-effective agent that reduces hospitalization for congestive heart failure and may prevent left ventricular dysfunction in uncomplicated hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: